- Recommendation ID
- TA320/1
- Question
- NICE recommends further research to better inform future cost-effectiveness models of relapsing-remitting multiple sclerosis. In particular, this research should include a more comprehensive synthesis of available evidence on the underlying disease progression of multiple sclerosis in the UK context, the impact of disability and relapses on preference-based measures of quality of life, and associated resource use and costs.
- Any explanatory notes
(if applicable) - None.
Source guidance details
- Comes from guidance
- Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
- Number
- TA320
- Date issued
- August 2014
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 15/10/2014 |